Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 111-118

  Kalff, V ^a   Hicks, R J ^a   MacManus, M P ^a   Binns, D S ^a   McKenzie, A F ^a   Ware, R E ^a   Hogg, A ^a   Ball, D L ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME;

EID: 0035156319     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.111     Document Type: Article

References (28)

1. Surgical staging of lung cancer
2. PET in lung cancer
3. Nuclear medicine procedures in lung cancer
4. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: Preliminary prospective evaluation
5. Staging non-small cell lung cancer by whole body positron emission tomography
6. Mediastinal lymph node staging of non-small cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
7. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with x-ray computed tomography
8. Non-small cell lung cancer: Nodal staging with FSDG PET versus CT with correlative lymph node mapping and sampling
9. Whole-body 18-FDG positron emission tomography in the staging of non-small cell lung cancer
10. Staging non-small cell lung cancer with whole-body PET
11. Selective use of PET scan in the preoperative staging of NSCLC
12. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study - The Leuven Lung Cancer Group
13. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET fusion images improve the localisation of regional lymph node metastases?
14. Cost effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis
15. Revisions to the international system for staging lung cancer
16. Continuous-slice PENN-PET: A positron tomograph with volume imaging capability
17. Lesion detection in whole body FDG PET using simultaneous emission transmission acquisition and OSEM reconstruction (SET-OSEM) versus emission only (OE) and FBP reconstruction: An ROC study
18. Clinical evaluation of processing techniques for attenuation correction with 137Cs in whole-body PET imaging
19. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
20. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer
21. Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2[F-18]-2-deoxy-D-glucose
22. Solitary pulmonary nodules: Detecton of malignancy with PET with 2-[F-18]-flouro-2-deoxy-D-glucose
23. Prospective investigation of positron emission tomography in lung nodules
24. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer
25. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnosis of oncological patients
26. Brain metastases of lung cancer: Diagnostic accuracy of positron emission tomography with fluorodeoxyglucose (FDG-PET)
27. Fluorine-18-FDG PET imaging is negative in bronchoalveolar lung carcinoma
28. Positron emission tomography (PET): Experience with a large-field-of-view three-dimensional PET scanner